The objective of this study is to determine whether @entity4088 therapy is an effective modality for the de novo treatment of @entity1 with @entity2013 . Twenty-two consecutive @entity1 with @entity2013 were included in the study and followed prospectively. These included 16 @entity1 and 6 @entity1 in whom pregnancy was not of concern. @entity4088 was administered once or twice a day depending on the @entity1 's preference. Ten @entity1 received 0.1 mg daily as a maintenance regimen and in the others the daily dose ranged from 0.05 to 0.5 mg. Eight @entity1 reported minor but tolerable side effects. One @entity1 had to be switched to @entity9229 because of intolerable @entity390 . After a mean of 12 months (range, 3-36), mean PRL levels declined from 3,135 ng/ml (range, 126-31,513) to 50 ng/ml (3-573), representing a mean PRL suppression of 88% (range, 0-99). PRL levels became normal in 15 @entity1 and decreased to 25-40 ng/ml in 3 others. The mean @entity5 volume shrinkage was 25% or greater in 19 @entity1 (86%), 50% or greater in 17 @entity1 (77%), and 75% or greater in 10 @entity1 (45%). @entity227 were reversible after @entity4088 therapy in all but 1 of 12 @entity1 with initially abnormal formal visual testing. Two out of 4 premenopausal @entity1 did not normalize PRL levels and had persistent @entity2589 . @entity251 was low in 14 @entity1 at presentation and normalized in 3 with @entity4088 therapy. We conclude that @entity4088 is a safe, inexpensive, and generally well-tolerated @entity935 agonist for the treatment of @entity2013 in @entity1 and @entity1 in whom pregnancy is not of concern. In these specific populations, @entity4088 may become the first-line therapy for treatment of @entity2013 .

@entity4088 as primary therapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men'] @entity227 :: ('MESH:D014786', 'Disease') :: ['Visual abnormalities'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['Testosterone'] @entity2013 :: ('MESH:D015175', 'Disease') :: ['macroprolactinomas'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity9229 :: ('MESH:C047047', 'Chemical') :: ['cabergoline'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity4088 :: ('MESH:D010479', 'Chemical') :: ['pergolide', 'Pergolide'] @entity2589 :: ('MESH:D009839', 'Disease') :: ['oligomenorrhea']
@entity2013 :: (MESH:D015175,Disease) :: ['macroprolactinomas']
